drugset / Trial / NCT01092689
The Role of Meat-borne Carcinogens in Pancreatic Cancer
Phase 1
Withdrawn
University of Minnesota
Lawrence Livermore National Laboratory · collabUniversity of Arkansas · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
We propose to recruit subjects scheduled for pancreatectomy as a treatment for pancreatic cancer. These subjects will ingest a very low dose of radiolabeled PhIP, a meat-derived carcinogen, and a small amount of resected tissue (waste) will be analyzed with highly sensitive technology to determine if this carcinogen binds to DNA in the pancreas.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-01
- Completion
- 2012-01
Outcome
Outcome not reported
Stopped: “Needed New IND per FDA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PhIP | Unknown | 84 ug | Oral |